State-of-the-Art Chemotherapy for Advanced Non-Small Cell Lung Cancer

Seminars in Oncology

Volumn 31, Issue 1 SUPPL. 1, 2004, Pages 68-74

  Ramalingam, Sakkaraiappan ^b   Belani, Chandra P ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; ISIS 3521; MITOMYCIN; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TIRAPAZAMINE; VASCULOTROPIN ANTIBODY; VINDESINE;

ADVANCED CANCER; AGING; ALOPECIA; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HEALTH STATUS; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 1242318822     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.12.017     Document Type: Article

References (32)

1. Rivera MP, Detterbeck FC, Loomis DP: Epidemiology and classification of lung cancer, in Detterbeck FC, Rivera MP, Socinksi MA (eds): Diagnosis and Treatment of Lung Cancer. ed 1. Philadelphia, PA, Saunders, 2001, pp 25-44
2. Bulzebruck H, Bopp R, Drings P, et al: New aspects in the staging of lung cancer: Prospective validation of the International Union Against Cancer TNM classification. Cancer 70:1102-1110, 1992
3. NSCLC Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909, 1995
4. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16:2459-2465, 1998
5. Gatzemeier U, von Pawel J, Gottfried M, et al: Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 18:3390-3399, 2000
6. Sandler AB, Nemunaitis J, Denham C, et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130, 2000
7. von Pawel J, von Roemeling R, Gatzemeier U, et al: Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATA-PULT 1 study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 18:1351-1359, 2000
8. Belani CP, Natale RB, Lee JS, et al: Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17:455a, 1998 (abstr 1751)
9. Schiller J, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
10. Kelly K, Crowley J, Bunn PA, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
11. Rodriguez J, Pawel J, Pluzanska A, et al: A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 202001314a (abstr 1252)
12. Gralla RJ, Rodrigues J, Von Pawel J, et al: Prospective analysis of quality of life (QOL) in a randomized multinational phase III study comparing docetaxel (D) plus either cisplatin (C) or carboplatin (Cb) with vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:300a, 2002 (abstr 1196)
13. Niho S, Nagao K, Nishiwaki Y, et al: Randomized multicenter phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18:492a, 1999 (abstr 1897)
14. Masuda N, Fukuoka M, Negoro S, et al: Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer: A multicenter phase III study. Proc Am Soc Clin Oncol 18:459a, 1999 (abstr 1774)
15. Lilenbaum RC, Herndon J, List M, et al: Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): A CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol 21:1a, 2002 (abstr 2)
16. Sederholm C: Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): A phase III study by the Swedish Lung Cancer Study Group (SLUSG). Proc Am Soc Clin Oncol 21:291a, 2002 (abstr 1162)
17. Georgoulias V, Ardavanis A, Agelidou M, et al: Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (D/C) in patients with inoperable advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:291a, 2002 (abstr 1163)
18. Alberola V, Camps C, Provencia M, et al: Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine (GV) followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small cell lung cancer (NSCLC): Results of a Spanish Lung Cancer Group phase III trial (GEPC/98-02). Proc Am Soc Clin Oncol 20:308a, 2001 (abstr 1229)
19. Rudd RM, Gower NH, James LE, et al: Phase III randomised comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:292a, 2002 (abstr 1164)
20. Van Meerbeeck JP, Smit EF, Lianes P, et al: A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncot 20:308a, 2001 (abstr 1228)
21. Gridelli C, Shepherd FA, Perrone F, et al: Gemvin III: A phase III trial of gemcitabine plus vinorelbine (GV) compared to cisplatin plus vinorelbine or gemcitabine chemotherapy (PCT) for stage IIIB or IV non-small cell lung cancer (NSCLC): An Italo-Canadian study. Proc Am Soc Clin Oncol 21:292a, 2002 (abstr 1165)
22. Georgoulias V, Papadakis E, Alexopoulos A, et al: Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: A randomized multicenter trial. Lancet 357:1478-1484, 2001
23. Lee-Chiong TL Jr, Matthay RA: Lung cancer in the elderly patient. Clin Chest Med 14:453-478, 1993
24. Hutchins LF, Unger JM, Crowley JJ, et al: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067, 1999
25. The Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91:66-72, 1999
26. Gridelli C, Perrone F, Cigolari S: The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase 3 trial: Gemcitabine + vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced NSCLC patients. Proc Am Soc Clin Oncol 20:308a, 2001 (abstr 1230)
27. Langer CJ, Manola J, Bernardo P, et al: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173-181, 2002
28. Kelly K, Giarritta S, Hayes S: Should older patients (pts) receive combination chemotherapy for advanced non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol 20:329a, 2001 (abstr 1313)
29. Kris MG, Natale RB, Herbst RS, et al: A phase II trial of ZD1839 ("Iressa") in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21:292a, 2002 (abstr 1166)
30. Fukuoka M, Yano S, Giaccone G, et al: Final results from a phase II trial of ZD1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL1). Proc Am Soc Clin Oncol 21:298a, 2002 (abstr 1188)
31. Herbst RS, Giaccone G, Schiller J, et al: Subset analyses of INTACT results for gefitinib (ZD1839) when combined with platinum-based chemotherapy for advanced non-small cell lunger cancer. Proc Am Soc Clin Oncol 22:627, 2003 (abstr)
32. Yuen A, Halsey J, Fisher G, et al: Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol 20:309a, 2001 (abstr 1234)